The global xerostomia therapeutics market is expected to be around of US$ 899.4 million by 2028 and a CAGR of 3.7% for the forecast period of 2023-2028.
sing instances of deadly diseases such as HIV, mouth cancer, diabetes, Alzheimer’s and other diseases propelling demand for effective xerostomia therapeutics across the globe. Increasing usage of radiotherapy and chemotherapy for effective cancer treatment majorly causes dry mouth or xerostomia to the patients. The radiation therapy affects the functioning of the salivary that last up few months after the treatment.
The easy availability of varied product portfolio is projected to fuel xerostomia therapeutics market share in several countries during the forecast period. Moreover, the presence of numerous players in the market is restraining the future revenue generation opportunities for the companies. The lack of awareness in several merging countries may hamper market growth over the projected time frame.
Global xerostomia therapeutics market is segregated on the basis of product as, salivary stimulants, salivary substitutes, and dentifrices. Based on type, the global xerostomia therapeutics market is segmented as over-the-counter and prescription.
Global xerostomia therapeutics market report provides geographic analysis covering regions such as North America, Europe, Asia Pacific, and Rest of World. The xerostomia therapeutics market for each region is further segmented for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Synedgen, Parnell Pharmaceuticals Inc, GlaxoSmithKline PLC, Lupin, Church & Dwight Co. Inc, Acacia Pharma, OraCoat, Hikma, Parnell Pharmaceuticals, and Pfizer Inc are among the major players in the global xerostomia therapeutics market share. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Xerostomia Therapeutics Market has been segmented as below:
Xerostomia Therapeutics Market, By Type
Xerostomia Therapeutics Market, By Product
Xerostomia Therapeutics Market, By Region
The report covers:
Report scope:
Global xerostomia therapeutics market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global xerostomia therapeutics market share. Major industry players with significant revenue share include Synedgen, Parnell Pharmaceuticals Inc, GlaxoSmithKline PLC, Lupin, Church & Dwight Co. Inc, Acacia Pharma, OraCoat, Hikma, Parnell Pharmaceuticals, and Pfizer Inc.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
Pumpkin Seed Oil Supplements Market
Veterinary/Animal Vaccines Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Driver 1
4.2.2. Driver 2
4.2.3. Driver 3
4.3. Restraints
4.3.1. Restraint 1
4.3.2. Restraint 2
4.4. Opportunities
4.4.1. Opportunity 1
4.4.2. Opportunity 2
4.5. Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
5. Xerostomia Therapeutics Market, By Type
5.1. Key Points
5.2. Over the counter
5.3. Prescription
6. Xerostomia Therapeutics Market, By Product
6.1. Key Points
6.2. Salivary Stimulants
6.3. Salivary Substitutes
6.4. Dentifrices
7. Competitive Landscape
7.1. Introduction
7.2. Recent Developments
7.2.1. Mergers &Acquisitions
7.2.2. New Product Developments
7.2.3. Portfolio/Production Capacity Expansions
7.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
7.2.5. Others
8. Company Profile
8.1. Synedgen
8.1.1. Company Overview
8.1.2. Product/Service Landscape
8.1.3. Financial Overview
8.1.4. Recent Developments
8.2. Parnell Pharmaceuticals Inc
8.2.1. Company Overview
8.2.2. Product/Service Landscape
8.2.3. Financial Overview
8.2.4. Recent Developments
8.3. GlaxoSmithKline PLC
8.3.1. Company Overview
8.3.2. Product/Service Landscape
8.3.3. Financial Overview
8.3.4. Recent Developments
8.4. Lupin
8.4.1. Company Overview
8.4.2. Product/Service Landscape
8.4.3. Financial Overview
8.4.4. Recent Developments
8.5. Church & Dwight Co. Inc
8.5.1. Company Overview
8.5.2. Product/Service Landscape
8.5.3. Financial Overview
8.5.4. Recent Developments
8.6. Acacia Pharma
8.6.1. Company Overview
8.6.2. Product/Service Landscape
8.6.3. Financial Overview
8.6.4. Recent Developments
8.7. OraCoat
8.7.1. Company Overview
8.7.2. Product/Service Landscape
8.7.3. Financial Overview
8.7.4. Recent Developments
8.8. Hikma
8.8.1. Company Overview
8.8.2. Product/Service Landscape
8.8.3. Financial Overview
8.8.4. Recent Developments
8.9. Parnell Pharmaceuticals
8.9.1. Company Overview
8.9.2. Product/Service Landscape
8.9.3. Financial Overview
8.9.4. Recent Developments
8.10. Pfizer
8.10.1. Company Overview
8.10.2. Product/Service Landscape
8.10.3. Financial Overview
8.10.4. Recent Developments
The Xerostomia Therapeutics Market has been segmented as below:
Xerostomia Therapeutics Market, By Type
Xerostomia Therapeutics Market, By Product
Xerostomia Therapeutics Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
